Male sex is associated with higher mortality among patients with hepatocellular carcinoma
1. In patients with hepatocellular carcinoma, male sex was associated with significantly higher mortality compared to female sex, but the ...
1. In patients with hepatocellular carcinoma, male sex was associated with significantly higher mortality compared to female sex, but the ...
1. Use of Sodium-Glucose Cotransporter 2 (SGLT-2) inhibitors among adults with cirrhosis receiving diuretic therapy was associated with lower incidence ...
1. Progression-free survival was significantly greater in the durvalumab plus bevacizumab group compared to placebo. 2. Common treatment-related adverse events ...
1. Overall vaccine efficacy ranged from 83.1% to 86.6% during the 10-year period. 2. Detectable concentrations of antibodies persisted at ...
1. Overall vaccine efficacy ranged from 83.1% to 86.6% during the 10-year period. 2. Detectable concentrations of antibodies persisted at ...
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without ...
1. Patients in the camrelizumab-rivoceranib group reported significantly greater progression-free survival than the sorafenib group. 2. Treatment-related deaths were comparable ...
1. This quantitative study found that buprenorphine/naloxone can be safely administered to patients with acute hepatitis A without increased risk ...
1. Administration of intravenous terlipressin was shown to improve kidney function in hospitalized patients with type 1 hepatorenal syndrome. 2. ...
1. Administration of human albumin solution was shown not to lead to any clinical improvement in patients hospitalized with cirrhosis. ...
3-day free trial · cancel anytime
Then $4.99/month. Manage renewal in your account.
NPI Lookup · Free
Search by name or NPI number, live from the CMS NPI Registry.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
Monthly plan selected: $4.99 /month.
3-day free trial · cancel anytime
Then $4.99/month. Manage renewal in your account.
Yearly plan selected: $49.90 /year.
2 months free
Then $49.90/year.
Already a member? Sign in